Clinical trials: G-CSF
Bone Pain
Loratadine for Improvement of Bone Pain in Patients With Chronic Granulocyte-Colony Stimulating Factor (G-CSF) Use
G-CSF causes a release of histamine that may be a cause of chronic bone pain. Loratadine targets histamine, and so may be effective in reducing bone pain.The researchers plan to prospectively assess the effectiveness of…
- Trial name
- NCT03883386
- Testing
- Loratadine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Michigan
Hematologic Neoplasms
National Marrow Donor Program Long-Term Donor Follow-Up
This is an observational study of unstimulated bone marrow (BM) and filgrastim-mobilized peripheral blood stem cell (PBSC) donors.
- Trial name
- LTDFU (NCT01362179)
- Where
- 29 sites in United States, Puerto Rico
- Volunteers
- 21,974 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
Chediak-Higashi Syndrome, Graft Versus Host Disease
Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders
OBJECTIVES: I. Determine the efficacy of unrelated donor hematopoietic stem cell transplantation in the treatment of patients with life threatening hemophagocytic disorders. II.
- Conditions
- Chediak-Higashi Syndrome, Graft Versus Host Disease, X-Linked Lymphoproliferative Syndrome, Familial Erythrophagocytic Lymphohistiocytosis
- Trial name
- NCT00006056
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Fairview University Medical Center
Multiple Myeloma
Plerixafor Plus Granulocyte Colony-stimulating Factor (G-CSF) For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Multiple Myeloma
Primary Objective: To determine if Multi Myeloma (MM) patients mobilized with granulocyte colony-stimulating factor (G-CSF) plus plerixafor 240 μg/kg are more likely to achieve a target number of greater than or equal to 6 x 10^6…
- Trial name
- NCT02221479
- Testing
- plerixafor GZ316455, Filgrastim
- Where
- 5 sites in Japan
- Volunteers
- 14 people
- Sponsor
- Genzyme, a Sanofi Company
Leukemia
Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00002805
- Testing
- filgrastim, cladribine, cytarabine
- Where
- 38 sites in United States, Australia and 1 more
- Volunteers
- 115 people
- Sponsor
- Children's Oncology Group
Non-Hodgkin Lymphoma, Hodgkin Lymphoma
Auto Stem Cell Transplant for Lymphoma Patients
This is a phase II study of autologous transplant for patients with Hodgkin (HL) and non-Hodgkin lymphomas (NHL) including those who are HIV positive.
- Trial name
- NCT03125642
- Testing
- Etoposide, BCNU, AraC
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Leukemia
Combination Chemotherapy Followed By Filgrastim or Sargramostim in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim and sargramostim may increase the number of immune cells found…
- Trial name
- NCT00053131
- Testing
- filgrastim, sargramostim, cytarabine
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
Lymphoma
Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00002461
- Testing
- filgrastim, sargramostim, carmustine
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Montefiore Medical Center
Breast Cancer
Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery.
The purpose of this study is to determine how well this combination of chemotherapy drugs works with bevacizumab in eliminating primary tumor in the breast prior to surgery(pathological complete response or pCR in the breast).
- Trial name
- NCT00777673
- Testing
- Bevacizumab, nab-paclitaxel, carboplatin, doxorubicin hydrochloride, cyclophosphamide, PEG-Filgrastim
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- University of Tennessee Cancer Institute
Leukemia
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses…
- Trial name
- NCT00002831
- Testing
- Filgrastim, Busulfan, Cyclophosphamide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Effectiveness of Reduced GCSF Dosing in Patients With a Low to Moderate Risk of Febrile Neutropenia
The study aims to confirm that a reduced dosage of GCSF is effective in preventing febrile neutropenia among patients with breast cancer, treated with chemotherapy and presenting with a low to moderate risk of developing febrile…
- Trial name
- PAPALDO (NCT01658956)
- Testing
- GCSF administration on days 8 and 12 after chemotherapy
- Where
- Belgium
- Volunteers
- 142 people
- Sponsor
- Jules Bordet Institute
Prostate Cancer
Efficacy Study Evaluating Chemotherapy in Prostate Cancer
This clinical trial is designed on the basis of an unmet clinical need, as well as other factors including: 1) the ability to identify subjects at high risk of dying early from their disease, 2) the fact that hormonal therapy has…
- Trial name
- SensiCab (NCT01978873)
- Testing
- Cabazitaxel + Androgen deprivation therapy, Androgen deprivation therapy
- Where
- Sweden
- Volunteers
- 400 people
- Sponsor
- Örebro University, Sweden
Lymphoma
Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Low- or Intermediate-Grade Non-Hodgkin's Lymphoma
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy.
- Trial name
- NCT00006241
- Testing
- filgrastim, chemotherapy, in vitro-treated peripheral blood stem cell transplantation
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Breast Cancer
Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer
RATIONALE: Bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.
- Trial name
- NCT00003086
- Testing
- filgrastim, CAF regimen, carboplatin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Louisiana State University Health Sciences Center Shreveport
Myelodysplastic Syndromes
A Clinical Trial of Omacetaxine, Azacitidine, and Growth-Colony Stimulating Factor (G-CSF) for Myelodysplastic Syndromes (MDS)
The purpose of this study is to determine the safety and establish the maximum tolerated dose (MTD) of omacetaxine in combination with azacitidine and G-CSF in patients with relapsed and/or refractory MDS.
- Trial name
- NCT02835794
- Testing
- Omacetaxine, Azacitidine, G-CSF
- Where
- United States
- Sponsor
- University of Florida
Bortezomib, Acute Myeloid Leukemia
Bortezomib Combined With DAG Regimen in the Treatment of Refractory/Relapsed AML
In recent years, the efficacy of AML has been greatly improved, which is mainly due to the following aspects: the development of individualized treatment strategies based on genetic prognosis stratification, the application of…
- Trial name
- NCT05982756
- Testing
- DAG pre-excitation regimen with Bortezomib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhongnan Hospital
Lymphoma
Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First Relapse
RATIONALE: Drugs used in chemotherapy, such as pixantrone, cytarabine, methylprednisolone, and cisplatin, work in different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00069966
- Testing
- filgrastim, rituximab, cisplatin
- Where
- 29 sites in United States, Puerto Rico
- Sponsor
- Theradex
Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Germ Cell Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Conditions
- Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Teratoma
- Trial name
- NCT00002931
- Testing
- filgrastim, carboplatin, etoposide
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- City of Hope Medical Center
Lymphoma
Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma
The goal of this clinical research study is to see if high-dose chemotherapy (BEAM) and rituximab, given together with the new drug 90Y Zevalin, followed by a transplant of blood or marrow stem cells is safe.
- Trial name
- NCT01538472
- Testing
- Y Zevalin, In Zevalin, Rituxan
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Bone Marrow Transplantation, Hematopoietic Stem Cells
Hyperbaric Oxygen Therapy for Hematopoietic Progenitor Cell Collection in Poor Mobilizers
This is a pilot study to evaluate the efficacy of hyperbaric oxygen therapy (HBO2) for mobilizing hematopoietic progenitor cells from bone marrow to blood.
- Conditions
- Bone Marrow Transplantation, Hematopoietic Stem Cells, Multiple Myeloma, Lymphoma
- Trial name
- NCT02682953
- Testing
- Neupogen, Hyperbaric oxygen therapy, Plerixafor
- Where
- United States
- Sponsor
- University of Maryland, Baltimore